Receipt of Guideline-Concordant Care Lower for Black Colorectal Cancer Patients
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 14, 2023 -- Individuals racialized as Black and newly diagnosed with colorectal cancer (CRC) receive worse and less-timely guideline-concordant care, according to a study published online Nov. 8 in the Journal of Clinical Oncology.
Leticia M. Nogueira, Ph.D., M.P.H., from the American Cancer Society in Atlanta, and colleagues selected individuals aged 18 to 49 years racialized as non-Hispanic Black and White (self-identified) and newly diagnosed with CRC during 2004 to 2019. Individuals who received recommended care, which included staging, surgery, lymph node evaluation, chemotherapy, and radiotherapy, were considered to have received guideline-concordant care.
Overall, 20.8 and 14.5 percent of the 84,882 patients with colon cancer and 62,573 with rectal cancer, respectively, were racialized as Black. The researchers found that the likelihood of not receiving guideline-concordant care for colon and rectal cancers was increased for individuals racialized as Black (adjusted hazard ratios, 1.18 and 1.27, respectively). Among patients with colon and rectal cancer, 28.2 and 21.6 percent of the disparity, respectively, was explained by health insurance. Compared with individuals racialized as White, those racialized as Black had increased time to adjuvant chemotherapy for colon cancer and neoadjuvant chemoradiation for rectal cancer.
"With health insurance being the largest modifiable factor contributing to racial disparities in this study, it's critical to eliminate this barrier," Nogueira said in a statement. "Expanding access to health insurance coverage could help improve colorectal care and outcomes from individuals of all racialized groups."
Two authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.